These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 26633291)

  • 1. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.
    Schwartz DM; Bonelli M; Gadina M; O'Shea JJ
    Nat Rev Rheumatol; 2016 Jan; 12(1):25-36. PubMed ID: 26633291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
    Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
    Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cytokine signaling in autoimmunity: back to the future and beyond.
    Hirahara K; Schwartz D; Gadina M; Kanno Y; O'Shea JJ
    Curr Opin Immunol; 2016 Dec; 43():89-97. PubMed ID: 27821272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
    T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
    BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
    Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
    Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibitors: Is specificity at all relevant?
    Gadina M
    Semin Arthritis Rheum; 2024 Feb; 64S():152327. PubMed ID: 38007359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
    Welsch K; Holstein J; Laurence A; Ghoreschi K
    Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinases: an ideal target for the treatment of autoimmune diseases.
    Gadina M
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S70-2. PubMed ID: 24326567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jakpot! New small molecules in autoimmune and inflammatory diseases.
    Ghoreschi K; Gadina M
    Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Bonelli M; Kerschbaumer A; Kastrati K; Ghoreschi K; Gadina M; Heinz LX; Smolen JS; Aletaha D; O'Shea J; Laurence A
    Ann Rheum Dis; 2024 Jan; 83(2):139-160. PubMed ID: 37923366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
    Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ
    Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
    Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
    J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors: Ten years after.
    Spinelli FR; Meylan F; O'Shea JJ; Gadina M
    Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of the Jak/STAT pathway.
    Aittomäki S; Pesu M
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):18-23. PubMed ID: 24164900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.
    Xu P; Shen P; Yu B; Xu X; Ge R; Cheng X; Chen Q; Bian J; Li Z; Wang J
    Eur J Med Chem; 2020 Apr; 192():112155. PubMed ID: 32120325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
    Clark JD; Flanagan ME; Telliez JB
    J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K
    Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK/STAT: Why choose a classical or an alternative pathway when you can have both?
    Puigdevall L; Michiels C; Stewardson C; Dumoutier L
    J Cell Mol Med; 2022 Apr; 26(7):1865-1875. PubMed ID: 35238133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.